Abstract
Care during the final phase of life can present unique challenges for the health care provider. Although there is a spectrum of options for home care, the most comprehensive service for patients with limited life expectancy is hospice. It provides a patient and their family with an interdisciplinary health care team that works together to create a cohesive plan for pain and symptom management. Hospice referral is initiated by a physician that certifies a limited life expectancy based on Medicare guidelines.
Regardless of the diagnosis, most patients evolve through a similar series of signs and symptoms as they near death. The delivery of nutrition and hydration becomes difficult, and in many cases, detrimental to the overall comfort of the patient. Traditional modes of medication delivery for symptom management can also become problematic, often requiring specialized knowledge of alternative modes or medications.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Dame Cicely Biography – Cicely Saunders International. Home – Cicely Saunders International. http://www.cicelysaundersfoundation.org/about-us/dame-cicely-biography. Web 10 July 2011.
National Hospice Foundation. The history of hospice. http://www.nationalhospicefoundation.org/i4a/pages/index.cfm?pageid=218. Web 10 July 2011.
Sullivan P. Florence S. Wald, 91; U.S. Hospice Pioneer. Washington Post. http://www.washingtonpost.com/wp-dyn/content/article/2008/11/12/AR2008111202953.html. 13 Nov 2008.
The Hospice and Palliative Care Association (HPCAI). NHPCO Facts & Figures. http://www.nhpco.org/files/public/Statistics_Research/NHPCO_facts_and_figures.pdf. Web 10 July 2011.
The National Hospice and Palliative Care Organization. What is hospice and palliative care? http://www.nhpco.org/i4a/pages/index.cfm?pageid=4648. Web 16 July 2011.
The National Hospice and Palliative Care Organization. Levels of care. http://www.nhpco.org/i4a/pages/index.cfm?pageid=5504. Web 16 July 2011.
Medicare Payment Advisory Commission. A Data Book: Healthcare spending and the Medicare Program, June 2010. 2010.
Office of the Assistant Secretary for Planning and Evaluation, HHS. Important questions for hospice in the next century: appendices. http://aspe.hhs.gov/daltcp/reports/impquesa.htm. Web 21 May 2011.
Mitchell SL, Kiely DK, Hamel MB, et al. Estimating prognosis for nursing home residents with advanced dementia. JAMA. 2004;291:2734–40.
Crooks V, Waller S, et al. The use of the Karnofsky Performance Scale in determining outcomes and risk in geriatric outpatients. J Gerontol. 1991;46:M139–44.
Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol. 1984;2:187–93.
Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model. Prediction of survival in heart failure. Circulation. 2006;113:1424–33.
Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Eng J Med. 2004;350(10):1005–12.
Said A, et al. Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease. J Hepatol. 2004;40:897–903.
Celli Beddhu S, Bruns FJ, Saul M, Seddon P, Zeidel ML. A simple comorbidity scale predicts clinical outcomes and costs in dialysis patients. Am J Med. 2000;108:609–13.
Miskulin DC, Martin AA, Brown R, et al. Predicting 1-year mortality in an outpatient hemodialysis population: a comparison of comorbidity instruments. Nephrol Dial Transplant. 2004;19:413–20.
Wright AA, Katz IT. Letting go of the rope – aggressive treatment, hospice care, and open access. N Engl J Med. 2007;357:324–7.
Candy B, Jones I, Drake R, Leurent B, King M. Interventions for supporting informal caregivers of patients in the terminal phase of a disease (Review). Cochrane Libr. 2011;9:1–75.
Downing M, Lesperance M, Lau F, Yang J. Survival implications of sudden functional decline as a sentinel event using the palliative performance scale. J Palliat Med. 2010;13:549–57.
Lunney J, Lynn J, Hogan C. Profiles of older Medicare decedents. J Am Geriatr Soc. 2002;50:1108–12.
Guralnik J, LaCroix A, Branch L, Kasl S, Wallace R. Morbidity and disability in older person in the years prior to death. Am J Public Health. 1991;81:443–7.
Teno J, Weitzen S, Fennell ML, Mor V. Dying trajectory in the last year of life: does cancer trajectory fit other diseases? J Palliat Med. 2001;4:457–64.
Minino A, Smith B. Deaths preliminary data for 2000. Natl Vital Stat Rep. 2001;49:1–40.
Lynn J. Serving patients who may die soon and their families: the role of hospice and other services. JAMA. 2001;285:925–32.
Kasven-Gonzalez N, Souverain R, Miale S. Improving quality of life through rehabilitation in palliative care: case report. Palliat Support Care. 2010;8(3):359–69.
Marin M, Laviano A, Pichard C. Nutritional intervention and quality of life in adult oncology patients. Clin Nutr. 2007;26(3):289–301.
Cline D. Nutrition issues and tools for palliative care. Home Healthc Nurse. 2006;24(1):54–7.
Clary P, Lawson P. Pharmacologic pearls for end-of-life care. Am Fam Physician. 2009;79(12):1059–65.
Adam J. ABC of palliative care: the last 48 hours. Br Med J. 1997;315(7122):1600–3.
Grond S, Zech D, Diefenbach C, Bischoff A. Prevalence and pattern of symptoms in patients with cancer pain: a prospective evaluation of 1635 cancer patients referred to a pain clinic. J Pain Symptom Manage. 1994;9:372–82.
Skaer T. Transdermal opioids for cancer pain. Health Qual Life Outcomes. 2006;4(24):1–9.
Kornick C, Santiago-Palma J, Moryl N, Payne R, Obbens E. Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain. Drug Saf. 2003;26:951–73.
Evans H, Easthope S. Transdermal buprenorphine. Drugs. 2003;63:1999–2010.
LeGrand S, Walsh D. Scopolamine for cancer-related nausea and vomiting. J Pain Symptom Manage. 2010;40(1):136–41.
Altman R, Barthel H. Topical therapies for osteoarthritis. Drugs. 2011;71(10):1259–79.
Payne R, Chandler S, Einhaus M. Guidelines for the clinical use of transdermal fentanyl. Anticancer Drugs. 1995;6:50–3.
Fonzo-Christe C, Vulkasovic C, Wasilewski-Rasca A, Bonnabry P. Subcutaneous administration of drugs in the elderly: survey of practice and systematic literature review. Palliat Med. 2005;19:208–19.
Leppert W. Role of intranasal fentanyl in breakthrough pain management in cancer patients. Cancer Manag Res. 2010;2:225–32.
Nagda C, Chotai N, Nagda D, Patel S, Patel U. Development and characterization of mucoadhesive microspheres for nasal delivery of ketorolac. Pharmazie. 2011;66(4):249–57.
Stote R, Miller M, Marbury T, Shi L, Strange P. Enhanced absorption of Nasulin, an ultrarapid-acting intranasal insulin formulation, using single nostril administration in normal subjects. J Diabetes Sci Technol. 2011;5(1):113–9.
Reid C, Hatton R, Middleton P. Case report: prehospital use of intranasal ketamine for pediatric burn injury. Emerg Med. 2011;28(4):328–9.
Mystakidou K, Tsilika E, Tsiatas M, Vlahos L. Oral transmucosal fentanyl citrate in cancer pain management: a practical application of nanotechnology. Int J Nanomedicine. 2007;2(1):49–54.
Anderson M, Tambe P, Sammons H, Mulla H, Cole R, Choonara I. Pharmakinetics of buccal and intranasal lorazepam in healthy adult volunteers. Eur J Clin Pharamacol. 2012;68(2):155–9.
Van Hoogdalem E, De Boer A, Breimer D. Pharmacokinetics of rectal drug administration. Part I. General considerations and clinical applications of centrally acting drugs. Clin Pharmacokinet. 1991;21(1):11–26.
Plonk W, Arnold R. Terminal Care: the last weeks of life. J Palliat Med. 2005;8(5):1042–54.
Ferris F, von Gunten C, Emanuel L. Competency in end-of-life care: last hours of life. J Palliat Med. 2003;6:605–13.
Morita T, Tsunoda J, Inoue S, Chihara S. Risk factors for death rattle in terminally ill cancer patients. Palliat Med. 2000;14:19–23.
Back I, Jenkins K, Blower A, Beckhelling J. A study comparing hyoscine hydrobromide and glycopyrrolate in the treatment of death rattle. Palliat Med. 2001;15:329–36.
Casarett D, Inouye S. Diagnosis and management of delirium near the end of life. Ann Intern Med. 2001;135:32–40.
Ingham J, Breitbart W. Epidemiology and clinical features of delirium. In: Portenoy RK, Bruera E, editors. Topics in palliative care, vol. 1. New York: Oxford University Press; 1997. p. 7–20.
Morita T, Hirai K, Sakaguchi Y, Tsuneto S, Shima Y. Family perceived distress from delirium-related symptoms of terminally ill cancer patients. Psychosomatics. 2004;45:107–13.
Morrison R, Magaziner J, Gilbert M, Koval K, McLaughlin M, Orosz G, Strauss E, Siu A. Relationship between pain and opioid analgesics on the development of delirium following hip fracture. J Gerontol. 2003;58:76–81.
Lawlor P, Gagnon B, Mancini I, Pereira J, Hanson J, Suarez-Almazor M, Bruera E. Occurrence, causes, and outcomes of delirium in patients with advanced cancer: a prospective study. Arch Intern Med. 2000;160:786–94.
Breitbart W, Marotta R, Platt M, Weisman H, Derevenco M, Grau C, Corbera K, Raymond S, Lund S, Jacobson P. A double blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry. 1996;153:231–7.
Finucane T. Delirium at the end of life. Ann Intern Med. 2002;137:295.
Glare P, Virik K, Jones M, Hudson M, Eychmuller S, Simes J, Christakis N. A systematic review of physicians’ survival predictions in terminally ill cancer patients. BMJ. 2003;327:195.
Morita T, Ichiki T, Tsunoda J, Inoue S, Chihara S. A prospective study on the dying process in terminally ill cancer patients. Am J Hosp Palliat Care. 1998;15:217–22.
Wildiers H, Menten J. Death rattle: prevalence, prevention, and treatment. J Pain Symptom Manage. 2002;23:310–7.
Mercandante S, Casuccio A, Fulfaro F. The course of symptom frequency and intensity in advanced cancer patients followed at home. J Pain Symptom Manage. 2000;20:104–12.
Ellershaw J, Ward C. Care of the dying patient: the last hours or days of life. BMJ. 2003;326:30–4.
Lynn J, Teno J, Phillips R, Wu A, Desbiens N, Harrold J, Claessens M, Wenger N, Kreling B, Connors Jr A. Perceptions by family members of the dying experience of older and seriously ill patients. Ann Intern Med. 1997;126:97–106.
Hickman S, Tilde V, Tolle S. Family reports of dying patients distress: the adaptation of a research tool to assess global symptom distress in the last week of life. J Pain Symptom Manage. 2001;22:565–71.
Addington-Hall J, McCarthy M. Dying from cancer: results of a national population-based investigation. Palliat Med. 1995;9:295–305.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Appendices
Review Questions
-
1.
An 83 year-old man with end stage COPD comes to your office to discuss goals of care. His breathing has deteriorated over the last few months, and he has been hospitalized four times this year. He states that he would like to avoid returning to the hospital if he were to get sick again and would like to focus on comfort. He heard that hospice can offer him the opportunity to have symptom management to focus on comfort for his remaining days. Which of the following describes the covered services and items he could receive?
-
(a)
Daily in-home caregiver
-
(b)
Room and board at a nursing facility
-
(c)
Hospital bed, oxygen, and commode for home use
-
(d)
Homemaking assistance with cooking and light housework
-
(a)
-
2.
Which of the following statements regarding Hospice care is false?
-
(a)
Hospice care includes coverage for durable medical equipment, medications, and home visits for pain and symptom management
-
(b)
Once signed on to the Medicare Hospice benefit, patient visits to their Primary Care Physician (PCP) for a hospice related diagnosis are not covered
-
(c)
Hospice care is revoked if a patient elects to go to the Emergency department for an acute health issue related to their hospice diagnosis
-
(d)
In order to receive Hospice benefits, the patient must agree to “Do Not Resuscitate” Status
-
(a)
-
3.
A 73 year-old patient with end stage dementia and failure to thrive on Hospice begins to stabilize. Her oral intake is fair with hand feeding, she has not had pneumonia or a urinary infection in over 1 year, and she continues to have periods of lucidity where she can hold a limited conversation. Which of the following actions is most appropriate?
-
(a)
Discharge the patient from Hospice; she may re-enroll in the future as her condition progresses
-
(b)
Keep her on hospice but provide her with a reduced number of nurse visits, as she is doing well enough with only a bath aid visiting weekly
-
(c)
Keep her on hospice for a limited period of 1 month and monitor her for disease progression
-
(d)
Discuss her case with her former primary care physician before making a decision
-
(a)
-
4.
A patient with stage IV liver cancer is in under home hospice care, with her husband as her primary caregiver. She has intense pain and nausea, and is significantly encephalopathic and agitated. Her husband and nurse are having difficulty controlling her symptoms. Which of the following is false regarding treatment options?
-
(a)
This patient could benefit from a home visit from the hospice physician for evaluation
-
(b)
The patient could be transferred via EMS to the emergency department for a few hours of intensive symptom management while remaining on hospice care
-
(c)
The patient would qualify for general inpatient care due to her refractory symptoms
-
(d)
The patient’s uncontrolled symptoms qualify her for continuous nursing care in the home for continuous pain control and monitoring
-
(a)
-
5.
What is the current average length of stay on hospice?
-
(a)
10–20 days
-
(b)
3–4 months
-
(c)
Over 8 months
-
(d)
80–100 days
-
(a)
-
6.
A 72-year-old terminally ill female is showing decreased awareness of his surroundings, decreased oral intake of solids or liquids, and is no longer able to get out of bed. The most likely explanation for this constellation of findings is:
-
(a)
Loss of hope
-
(b)
Impending death
-
(c)
Depression
-
(d)
Uremia
-
(a)
-
7.
A 24-year-old palliative care patient with terminal breast cancer with metastasis to bone takes oral narcotics regularly for bone pain. The patient is no longer able to swallow. What is an alternative route of medication administration while under hospice care at home?
-
(a)
Topical salicylates
-
(b)
Transdermal scopolamine
-
(c)
Transdermal buprenorphine
-
(d)
Topical capsaicin
-
(a)
-
8.
A 61-year-old male is in his final stages of death and now under palliative “terminal” sedation. The primary goal with this type of sedation is:
-
(a)
Relief of intractable pain or suffering
-
(b)
Hasten the onset of death
-
(c)
Improved tissue oxygenation
-
(d)
Reduction in opioid medication usage
-
(a)
-
9.
An 87-year-old home hospice patient becomes increasingly less mobile and is physically limited to lying in her bed. A common complication of immobility while caring for a patient like this is:
-
(a)
Joint laxity
-
(b)
Hamstring hypertrophy
-
(c)
Pressure ulcers
-
(d)
Cerebral vascular accidents
-
(a)
-
10.
A terminally ill patient has advanced disease due to pancreatic cancer. The patient is cachectic and now lost the ability to swallow. The patient’s family is concerned for the patient’s nutritional status. The following are reasons to withhold nutrition except:
-
(a)
There are metabolic derangements associated with total parenteral nutrition
-
(b)
Aspiration and infections are possible with tube feeds
-
(c)
Starvation produces a euphoric state that increases comfort
-
(d)
Forcing food and fluids will help to prolong or enhance life
-
(a)
Answers
-
1.
(c)
-
2.
(d)
-
3.
(a)
-
4.
(b)
-
5.
(d)
-
6.
(b). While caring for someone with a terminal illness, the terminal phase of the illness can be one of the most challenging times. The terminal phase of an illness is defined as the time when a person’s disease process is incurable and their health deteriorates to the point where he or she is not expected to live more than a few days, weeks, or months. The signs and symptoms of impending death are often very similar, even in patients with very different terminal illnesses. Those caring for patients during this stage should be familiar with the common signs and symptoms of impending death so that he or she can educate the patient and caregivers about the dying process and support patients and caregivers through the patient’s death. With impending death, the patient has decreasing interest and awareness of his/her surroundings and a reduced desire or ability to move around. The patient will have a marked decrease in food or fluid intake and often develops difficulty with swallowing.
-
7.
(c). Pharmacologic symptom management can improve the quality of life of patients with a severe life-limiting illness. Although pharmacotherapy is only one component of end-of-life care, ensuring timely access to needed medication is a fundamental component of effective palliative care with increasing importance as death approaches. The loss of an oral intake route is a possibility that can occur at any time; therefore, the need for an effective alternate route for administering medication may become more urgent due to the inability to swallow. Additionally, since parenteral medications may not be available emergently, medications delivered via alternate routes should be made accessible for immediate administration. Transdermal buprenorphine is now being prescribed in the USA, but was initially used in Europe and Australia for chronic and cancer pain management. Buprenorphine’s mixed agonist/antagonist activity, dosage ceiling, and high affinity to the opiate receptor limit its use to those patients who do not already require large daily doses of opioids. Thus, buprenorphine may not be an appropriate medication for some patients with advanced unremitting cancer pain. Transdermal scopolamine is effective for severe drug-resistant nausea and vomiting in advanced cancer. It is most appropriate for vestibular causes of nausea and vomiting precipitated or exacerbated by head or body movement, with or without dizziness. Topical salicylates and capsaicin are available in the US without a prescription, but neither has shown substantial efficacy in clinical trials, and both have the potential to cause serious adverse reactions. Accidental poisonings have been reported with salicylates, and concerns exist that capsaicin-induced nerve desensitization may not be fully reversible and that its autonomic nerve effects may increase the risk of skin ulcers in diabetic patients.
-
8.
(a). The main goals of palliative care involve the relief of pain and suffering in the dying patient. Terminal/palliative sedation describes the use of sedative agents to treat pain or suffering in the dying patient when other treatment measures are ineffective. This type of sedation is used to relieve intractable symptoms in the dying patient, not to expedite the dying process.
-
9.
(c). As a patient becomes progressively less mobile with advanced stages of his/her disease, there are numerous complications associated with immobility. Complications include muscle atrophy, constipation, joint stiffness and pain, urinary tract infection, increased clotting risk, and pressure ulcers. Pathologic fractures are not increased with immobility. Prevention of pressure ulcers can be maximized with the use of turning and positioning techniques.
-
10.
(d). Starvation and dehydration are not caused by lack of intake but by the disease process itself. Providing or even forcing food and fluids will not prolong or enhance life and may be a burden or detrimental. A healthy individual has an anabolic metabolism, which can use nutrients to build and repair tissue. However, during the dying process, the body shifts from an anabolic to a catabolic state. It is this catabolic condition that leads to starvation and dehydration. This shift is a natural part of the dying process and occurs whether or not food and fluids are provided. Furthermore, there is a possibility of additional problems due to complications of central line infections and metabolic derangement associated with total parenteral nutrition (TPN). Even tube feeding is not without risks, which include dislodgement, infection, discomfort, and aspiration. It is often not realized that starvation produces a euphoric state that increases comfort. As the body uses fat as the main energy source and ketones build up, the resulting ketonemia causes euphoria.
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Capasso, J., Kim, R.B., Perret, D. (2013). Hospice for the Terminally Ill and End-of-Life Care. In: Vadivelu, N., Kaye, A., Berger, J. (eds) Essentials of Palliative Care. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5164-8_4
Download citation
DOI: https://doi.org/10.1007/978-1-4614-5164-8_4
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-5163-1
Online ISBN: 978-1-4614-5164-8
eBook Packages: MedicineMedicine (R0)